Cyclerion Therapeutics jumps on MIT deal to develop depression drug

Korsana Biosciences

24/09/2025 11:26

** Shares of drug developer Cyclerion Therapeutics CYCN.O rise 43% to $4.33 premarket

** Co said late on Tuesday it is relaunching as a neuropsychiatric-focused firm after signing a licensing deal with the Massachusetts Institute of Technology

** Its lead program targets treatment-resistant depression using anesthetic-based tech

** A mid-stage trial is expected to begin in 2026 with data in 2027, co said

** As of last close, stock down 6.2% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))